Thursday, November 29, 2012

Medical News

Medical News


Evidence of neurobiologic differences between bipolar subtypes

Posted: 29 Nov 2012 04:00 PM PST

Taiwanese researchers have found differences in fronto-limbic metabolism and executive function between patients with bipolar disorder I and II.

Poor empathy may feature in common psychiatric conditions

Posted: 29 Nov 2012 04:00 PM PST

Individuals with schizophrenia, bipolar disorder, or depression may be less empathic than individuals without these conditions, according to German study results.

Evidence of neurobiologic differences between bipolar subtypes

Posted: 29 Nov 2012 04:00 PM PST

Taiwanese researchers have found differences in fronto-limbic metabolism and executive function between patients with bipolar disorder I and II.

Poor empathy may feature in common psychiatric conditions

Posted: 29 Nov 2012 04:00 PM PST

Individuals with schizophrenia, bipolar disorder, or depression may be less empathic than individuals without these conditions, according to German study results.

Poor empathy may feature in common psychiatric conditions

Posted: 29 Nov 2012 04:00 PM PST

Individuals with schizophrenia, bipolar disorder, or depression may be less empathic than individuals without these conditions, according to German study results.

Imaging window into future for brain injury patients

Posted: 28 Nov 2012 04:00 PM PST

A model based on quantitative diffusion tensor imaging findings predicts outcomes after severe traumatic brain injury better than current methods, shows a multicenter study.

High–fructose corn syrup use linked to diabetes

Posted: 28 Nov 2012 04:00 PM PST

Countries that have opted to use high-fructose corn syrup in their food and drink industry have a 20% higher mean prevalence of diabetes than countries that have minimal use of or do not use the sweetener.

Reoperation not reliable indicator for hernia recurrence

Posted: 28 Nov 2012 04:00 PM PST

Using reoperation rates as the indicator for recurrence after ventral hernia repair may underestimate the true recurrence rate, according to Danish study findings.

Regorafenib phase III results strongly support use in GIST

Posted: 28 Nov 2012 04:00 PM PST

Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.

Regorafenib phase III results strongly support use in GIST

Posted: 28 Nov 2012 04:00 PM PST

Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.

No comments:

Post a Comment